|
| 35313928 | Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. | Hered Cancer Clin Pract | 2022 |
| 35477169 | Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 36222710 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. | Clin Cancer Res | 2022 |
| 33670479 | Recurrent Mutations in <i>BRCA1</i>, <i>BRCA2</i>, <i>RAD51C</i>, <i>PALB2</i> and <i>CHEK2</i> in Polish Patients with Ovarian Cancer. | Cancers (Basel) | 2021 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 30829613 | The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer. | Cancer Biomark | 2019 |
| 31500890 | A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. | Gynecol Oncol | 2019 |
| 31239549 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. | Mod Pathol | 2019 |
| 30918533 | Selected features of breast and peritoneal cancers diagnosed in <i>BRCA1</i> carriers after risk-reducing salpingo-oophorectomy. | Hered Cancer Clin Pract | 2019 |
| 29304854 | Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer. | J Ovarian Res | 2018 |
| 29895125 | Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer. | Pol J Pathol | 2018 |
| 30519634 | Risk Model in Women with Ovarian Cancer Without Mutations. | Open Med (Wars) | 2018 |
| 29555990 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. | Br J Cancer | 2018 |
| 29584739 | Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? | PLoS One | 2018 |
| 29502561 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. | Mayo Clin Proc | 2018 |
| 29516012 | Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. | Biomed Res Int | 2018 |
| 29559794 | Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. | Onco Targets Ther | 2018 |
| 27623744 | The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. | Clin Genet | 2017 |
| 28182133 | HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases. | Dis Markers | 2017 |
| 29180933 | Implementation of an enhanced recovery after surgery (ERAS) protocol in a gynaecology department - the follow-up at 1 year. | Contemp Oncol (Pozn) | 2017 |
| 29049607 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. | JAMA Oncol | 2017 |
| 29089666 | Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer. | Dis Markers | 2017 |
| 28721066 | Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients. | Onco Targets Ther | 2017 |
| 28655131 | Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer. | Cancer Biomark | 2017 |
| 25940428 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. | Gynecol Oncol | 2016 |
| 28352846 | Ectopic pregnancy treatment by combination therapy. | Open Med (Wars) | 2016 |
| 27899969 | Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. | Oncol Lett | 2016 |
| 27595995 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. | J Med Genet | 2016 |
| 27268637 | MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors. | Asian Pac J Cancer Prev | 2016 |
| 27401727 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. | Int J Epidemiol | 2016 |
| 26747452 | Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2016 |
| 26928677 | Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. | J Ovarian Res | 2016 |
| 26753953 | Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status? | Tumour Biol | 2016 |
| 25750541 | Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions. | Onco Targets Ther | 2015 |
| 25849179 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. | JAMA | 2015 |
| 24037955 | The presence of prostate cancer at biopsy is predicted by a number of genetic variants. | Int J Cancer | 2014 |
| 25018782 | Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. | J Ovarian Res | 2014 |
| 24740199 | Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. | Cancer Epidemiol Biomarkers Prev | 2014 |
| 24764580 | Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. | Cancer Immunol Res | 2014 |
| 24528554 | HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases. | J Ovarian Res | 2014 |
| 24334819 | A rare case of peritoneal disseminated angiosarcoma 20 years after ovarian cancer diagnosis. | Gynecol Obstet Invest | 2014 |
| 24272484 | Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. | Cancer Res | 2014 |
| 24397359 | Conservative treatment of a young patient with thyroid carcinoma in adult ovarian teratoma - case report. | Gynecol Endocrinol | 2014 |
| 23192612 | Association of common WRAP 53 variant with ovarian cancer risk in the Polish population. | Mol Biol Rep | 2013 |
| 24191513 | [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries]. | Ginekol Pol | 2013 |
| 23722471 | A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. | Br J Cancer | 2013 |
| 23535731 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. | Nat Genet | 2013 |
| 23513043 | Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. | Cancer Epidemiol Biomarkers Prev | 2013 |
| 22669161 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. | Br J Cancer | 2012 |